Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Recombinant coagulation factors

P H Roddie1, C A Ludlam

  • 1Department of Haematology, Royal Infirmary of Edinburgh, UK.

Blood Reviews
|March 3, 1998
PubMed
Summary
This summary is machine-generated.

Recombinant coagulation factors offer a safer alternative to plasma-derived treatments for hemophilia, significantly reducing the risk of infectious agent transmission and revolutionizing patient care.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Pathogenesis and Management of Acquired Haemophilia.

Hematology (Amsterdam, Netherlands)·2016
Same author

Editorial introduction.

Haemophilia : the official journal of the World Federation of Hemophilia·2016
Same author

Hepatitis C virus genotypes in multi-transfused individuals.

Haemophilia : the official journal of the World Federation of Hemophilia·2016
Same author

Treatment of hepatitis C infection in haemophiliacs: the Edinburgh experience.

Haemophilia : the official journal of the World Federation of Hemophilia·2016
Same author

Guidelines on the diagnosis and management of chronic liver disease in haemophilia.

Haemophilia : the official journal of the World Federation of Hemophilia·2016
Same author

Hepatitis B serology and DNA detection in multitransfused haemophiliacs and factor VIII and IX concentrates.

Haemophilia : the official journal of the World Federation of Hemophilia·2016
Same journal

What population-based databases reveal about equity in access to hematopoietic cell transplant and cellular therapy.

Blood reviews·2026
Same journal

A tale of two sites - Distinct spatial differences between bone marrow and extramedullary AML.

Blood reviews·2026
Same journal

Treating large B-cell lymphoma: Current strategies and unmet needs across community and academic settings.

Blood reviews·2026
Same journal

MRD in multiple myeloma: Moving from "minimal" to "measurable".

Blood reviews·2026
Same journal

PRISMA-based systematic review on iron stores in repeat blood donors.

Blood reviews·2026
Same journal

Artificial intelligence applications in thrombotic thrombocytopenic Purpura: A systematic review of diagnostic, risk stratification, and prognostic models.

Blood reviews·2026
See all related articles

Area of Science:

  • Biotechnology
  • Hematology
  • Virology

Background:

  • Hemophilia care traditionally relied on plasma-derived coagulation factors.
  • Plasma-derived factors carry a risk of transmitting infectious agents like hepatitis C and HIV.
  • Technological advancements enable industrial-scale production of recombinant proteins.

Purpose of the Study:

  • To review the manufacturing process of recombinant coagulation factors.
  • To assess the safety and efficacy of recombinant coagulation factors through clinical trials.
  • To discuss challenges associated with transitioning to recombinant factor use, including viral safety and immunogenicity.

Main Methods:

  • Review of manufacturing processes for recombinant coagulation factors.
  • Analysis of clinical trial data on safety and efficacy.

Related Experiment Videos

  • Discussion of viral safety and immunogenicity concerns.

    • Main Results:

    • Recombinant coagulation factors have a very low risk of transmitting infectious agents.
    • The use of recombinant factors can eradicate the threat of viral infections like hepatitis C and HIV.
    • Established safety and efficacy profiles from clinical trials.

    Conclusions:

    • Recombinant coagulation factors represent a significant advancement in hemophilia care.
    • The shift to recombinant factors minimizes risks associated with viral transmission.
    • Ongoing evaluation of viral safety and immunogenicity is crucial for widespread adoption.